Prosztatarák trials, also abroad
1592 open Prosztatarák trials worldwide. Travel and costs are your own unless the study pays them; ask the study team first.
The same trial often runs in several countries
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) has 4 sites in Észtország and runs in 39 countries. If a site near you is full, another one may still take people.
See A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) in all 39 countries